Epidermal growth factor reproduces many of the effects of estrogen on the murine female reproductive tract and may partially mediate estrogen-induced growth and differentiation. The mechanism by which the actions of estrogens and epidermal growth factor (EGF) converge is unknown. The studies described herein were performed to investigate the possibility that some of the actions of EGF may be mediated through the estrogen receptor. A specific estrogen receptor (ER) antagonist inhibited estrogenlike effects of EGF in the mouse uterus, specifically induction of DNA synthesis and phosphatidylinositol turnover. In addition, EGF elicited enhanced nuclear localization of uterine ER and formation of a unique nuclear form of ER that is present after estrogen treatment. These in vivo observations indicated that EGF may elicit some of its actions by activation of nuclear ER. Thus, the effect of peptide growth factors on activation of a consensus estrogen response element was assessed in Ishikawa human endometrial adenocarcinoma cells, which contain negligible ER levels, and in BG-1 human ovarian adenocarcinoma cells, which contain abundant ER. EGF and TGFa induced transcriptional activation of a consensus estrogen response element (ERE) in an ER-dependent manner in both cell types. In addition, insulinlike growth factor (IGF-1) was as potent as 17,B-estradiol in BG-1 cells. Synergism between growth factors and estrogen was observed in both cell types, although synergism was not observed between the different classes of growth factors [i.e., transforming growth factor a (TGFa) and IGF-Il in BG-1 cells. The most potent activator of ERE-dependent transcription was a protein kinase C activator (TPA), which acted synergistically with 1 7festradiol. A protein kinase C inhibitor abolished the effect of TPA but not that of 1 7festradiol, IGF-I, or TGFa. A protein kinase A activator elicited ER-dependent activation of transcription and did not synergize with estrogen or growth factors. In conclusion, some physiologic actions of peptide growth factors are dependent on ER. Indeed, growth factors are capable of eliciting ER-dependent activation of an ERE. Both the protein kinase A and protein kinase C pathways can elicit ER-dependent transcriptional activation; however, it is unlikely that these pathways mediate the effects of peptide growth factors on the ER in BG-1 cells. -Environ Health Perspect 1 03(Suppl 7): 35-38 (1995) 
Introduction
It has been proposed that polypeptide growth factors may act as autocrine or paracrine mediators of biological actions of estrogen (1, 2) . The observations that estrogen induces mRNA and protein for peptide growth factors [epidermal growth factor (EGF), transforming growth factor a (TGFa), and insulinlike growth factor I (IGF-I)] (3-7) and their receptors (8) (9) (10) (11) EGF receptor-signaling pathway in steroid hormone regulation of uterine biology. Our laboratory has previously demonstrated a convergence between the actions of EGF and estradiol in the mouse uterus. EGF reproduced the stimulatory effects of estrogen on uterine DNA synthesis, lactoferrin gene expression, and phosphatidylinositol lipid metabolism in ovariectomized mice (12, 13) . Futhermore, administration of EGF-neutralizing antibodies before estradiol blocks estrogen-induced uterine epithelial cell proliferation, which suggests that the presence of EGF may be necessary for estrogen-induced responses (12) . Presently, the mechanisms by which the actions of estrogens and growth factors converge are unknown. These studies address the intriguing possibility that some biological effects of peptide growth factors, which are extracellular ligands, may be mediated through a nuclear steroid hormone receptor, namely, the estrogen receptor. Several reports in the literature support this hypothesis. First, two reports by Power et al. (14, 15) (20) .
The ability of an ER antagonist to block the cellular actions of EGF in the whole animal prompted an investigation of the effects of EGF on biochemical characteristics of the estrogen receptor (ER) (13) . Estrogen treatment rapidly enhances ER affinity for chromatin so that the ER is retained in the nuclear fraction after tissue homogenization. This phenomenon is quantitated by a 3H-estradiol-binding assay (21, 22) . Significant augmentation of nuclear ER levels was observed 1.5 hr after EGF pellet implantation or DES treatment. Enhanced nuclear retention of ER after EGF treatment was corroborated by immunodetection with H222 ER monoclonal antibody (a gift from Chris Nolan, Abbott Laboratories, Abbott Park, IL), which demonstrated that there was a larger quantity of protein in the ER-specific bands in the uterine nuclear fractions after EGF or DES treatment. The interaction of the ER with the estrogen response element (ERE) is a prerequisite for transcriptional activation. This property of ER found in uterine nuclear extracts from EGF-treated mice was compared to that found after DES treatment using a gel retardation assay (23) . In this assay, nuclear proteins were salt extracted from uterine homogenates and concentrated by ammonium sulfate precipitation. The nuclear extracts were incubated in the presence or absence of H222 ER antibody overnight followed by incubation with a 32P-labeled vitellogenin A2 consensus ERE. The resulting complexes were separated on a 5.625% polyacrylamide gel. The band-shifting pattern observed after EGF treatment was very similar to that seen after DES administration. The two specific ER-ERE complexes present after EGF or DES treatment were supershifted by H222 antibody, which demonstrated that immunoreactive ER was present in these complexes. These results suggest that the nuclear ER from EGFtreated mice interacts with an ERE in a manner similar to that observed after estrogen treatment. It has previously been demonstrated that estrogen treatment induces heterogenous nuclear ER forms of 65-and 66.5-kDa in uterine nudear extracts (22) and that the 66.5-kDa form is hyperphosphorylated ER (24) . Similar to the effect of estrogen, EGF treatment elicited the formation of the unique nuclear 66.5-kDa form of ER as assessed by immunodetection with H222 antibody. This form was not observed in the uterine cytosolic fractions from EGF-or DES-treated mice.
In summary, some estrogenlike effects of EGF in the uterus are dependent on the estrogen receptor. Furthermore Cells were frozen and thawed to obtain supernatants in which chloramphenicol acetyltransferase (CAT) enzyme activity was assayed, as previously described (25) .
Neither 17,-estradiol nor the peptide growth factors elicited a change in expression of the reporter gene (CAT) in the absence of ER transfection or in the presence of the control reporter vector (without ERE). However, in Ishikawa cells transfected with both vitA2 ERE pCAT and the ER expression vector, both EGF and TGFa as well as 17p-estradiol elicited transcription from the ERE. The activation of transcription by these agents was completely antagonized by the pure antiestrogen ICI 164,384 (1 x 10-7 M). These data are shown in Figure 1 . EGF in this figure refers to the mouse receptor-grade EGF used in the original pellet studies. It is clear from these data that the ER is required for the peptide growth factors to elicit transcription from the ERE. In addition, the effects of EGF and TGFa were inhibited approximately 70% by a mixture of human EGF receptor-neutralizing antibodies (Upstate Biotechnology Inc., Waltham, MA) (26, 27) , which demonstrated that the growth factors are dependent on the extracellular receptor for activity in this model. Neither basal transcription nor the effect of estradiol was inhibited by the antibodies. Interestingly, the combination of 170-estradiol (1 x 10-10) with either EGF or TGFa elicited EREdependent transcription of larger magnitude than the sum of their separate effects. [125I]-secondary antibody bound to the blot with an image analysis system from Molecular Dynamics (Sunnyvale, CA). As expected, estradiol treatment produced the same effect on ER levels. Increased proteolytic degradation of the mouse uterine ER after estradiol treatment has been previously reported (29) . Thus, the effect of the peptide growth factors was not dependent on enhanced ER levels. To rule out the possibility that the strong sv4O promoter could be responsible for the growth factor activity, we performed transfection experiments using a reporter vector that contained a minimal promoter, namely the adenovirus Elb TATA box (30) upstream of a vitellogenenin A2 promoter fragment containing a consensus ERE (a gift from John Cidlowski, University of North Carolina). Both TGFa and IGF-I activated transcription using this reporter vector. Transcriptional activation induced by TGFa, IGF-I, and 17,B-estradiol with either the sv4O or Elb minimal promoter was completely inhibited with ICI 164,384 ( X 10-7 M). Thus transcriptional activation in the BG-1 model is also dependent on the presence of the estrogen receptor.
Similar to the results obtained in the Ishikawa cells, both TGFa and IGF-I in combination with estradiol induced CATactivity levels that were greater than the sum of their separate activity. However, an interaction between IGF-I and TGFa treatments was not observed. One explanation for the observed synergism is that the growth factor-signaling mechanism induces ER conformational changes that are different from and are cooperative with those induced by ligand binding. Synergism between peptide growth factors and steroids has been reported previously. IGF-I and estrogen synergistically induced progesterone receptor levels in MCF-7 breast cancer cells (17) . Synergism between progesterone and EGF in T47D mammary tumor cells transfected with a progesterone response element has also been reported (31) . In addition, the interaction between dopamine and the ER in HeLa cells is very similar to that of EGF and ER (32) . Dopamine Aronica and Katzenellenbogen (33) have recently shown that 170-estradiol, IGF-I, and protein kinase A activators similarly enhance transcription (8-to 10-fold) from a minimal promoter-the ERE reporter construct transfected into ER-positive rat primary uterine cells. Transcriptional activation by these agonists was inhibited by ICI 164,384 or H8, a protein kinase A inhibitor. They concluded from these results that, in their system, the effects of IGF-I and 17j-estradiol are mediated through the activity of PKA. Similar to our findings in BG-1 cells, they did not observe synergism with the PKA agonist. Aronica and Katzenellenbogen (34) 
